4142 Share Price Performance
NT$18.80
-7.90 (-29.59%)
Price NT$18.80
Share PriceNT$18.80
There's No Escaping Adimmune Corporation's (TWSE:4142) Muted Revenues Despite A 26% Share Price Rise
Jan 13
Adimmune Corporation Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
4142 Community Narratives
There are no narratives available yet.
Recent 4142 News & Updates
Adimmune Corporation Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.54
- Gross Margin
- 24.04%
- Net Profit Margin
- -14.07%
- Debt/Equity Ratio
- 56.9%
Adimmune Corporation Competitors
Snowflake Analysis
About 4142
- Founded
- 1965
- Employees
- n/a
- CEO
- WebsiteView website
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Taiwanese Market Performance
- 7 Days: 5.0%
- 3 Months: 20.1%
- 1 Year: 18.3%
- Year to Date: 18.0%
Over the last 7 days, the market has risen 5.0%, driven by gains of 7.3% in the Information Technology sector. In the last year, the market has climbed 18%. Earnings are forecast to grow by 18% annually. Market details ›